Neurocrine Biosciences, Inc.

Dupont Pharmaceuticals Company

Dimitri Emil Grigoriadis

Chen Wang Liaw

Tilman Oltersdorf

Errol B DeSouza

Timothy W Lovenberg

Derek T Chalmers

Robert J Chorvat

Paul Joseph Gilligan

Paul E Aldrich

Argyrios Georgios Arvanitis

Christopher F O'Brien

Carl Nicholas Hodge

Zelda Rakowitz Wasserman

Robert Scott Cheeseman

Thomas E Christos

Sang William Tam

Everett Latham Scholfield

Paul John Krenitsky

CRFreceptor antagonists have the potential to directly inhibit ACTH release in patients with CAH and thereby allow normalization of androgen production while using lower, more physiologic doses of hydrocortisone, and thus reducing treatment-associated side effects.

Treatment of congenital adrenal hyperplasia

The present invention provides isolated nucleic acid molecules encoding CRFreceptors, recombinant expression vectors and host cells suitable for expressing such receptors, as well as compositions and methods which utilize such receptors.

[object Object]

The present invention provides isolated nucleic acid molecules encoding CRF receptors, recombinant expression vectors and host cells suitable for expressing such receptors, as well as compositions and methods which utilize such receptors.

Corticotropin-releasing factor2 receptors

1N-alkyl-n-arylpyrimidinamines and derivatives thereof

The present invention provides isolated nucleic acid molecules encoding CRF.sub.2 receptors, recombinant expression vectors and host cells suitable for expressing such receptors, as well as compositions and methods which utilize such receptors.

Isolated nucleic acid encoding corticotropin-releasing factor.sub.2

Growing community of inventors

Carlsbad, CA, United States of America

Dimitri Emil Grigoriadis